<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00634673</url>
  </required_header>
  <id_info>
    <org_study_id>HCPA05060</org_study_id>
    <nct_id>NCT00634673</nct_id>
  </id_info>
  <brief_title>Postprandial Fatty Acids and FABP2 in Type 2 Diabetes Mellitus (DM)</brief_title>
  <official_title>FABP2 Ala54Thr Genotype Influences the Postprandial Serum Fatty Acids Profile in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in type 2 diabetic patient's to evaluate the if there is a
      different response of serum lipids after a standard meal (rich in saturated fatty acids) in
      patients who have the presence of a genetic alteration. This alteration that will be
      evaluated is a polymorphism, change of an amino acid in the gene of FABP2. This gene that can
      influence the absorption of lipids in the intestine and subjects who have the altered
      genotype (presence of T allele) can have an abnormal lipid profile as compared to subjects
      without this genotype.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The presence of Ala54Thr polymorphism of intestinal fatty acid-binding protein 2
      gene (FABP2) might influence the intestinal absorption of dietary fatty acids (FAs) and has
      been associated with diabetic nephropathy.

      Objective: We studied the postprandial serum FAs in type 2 diabetic patients homozygous for
      Thr54 (TT; n = 11) or for Ala54 (AA; n = 15) after a standard meal.Design: Patients received
      a sandwich (7.23 kcal/kg-total energy; 43.35% fat, 21.95% protein, and 34.70% carbohydrate)
      in the morning after 12-h fasting and FAs in chylomicrons (gas chromatograph), plasma
      glucose, and serum triacylglycerols were measured at 0, 2, 4, 6 and 8 h. Results: TT and AA
      patients did not differ regarding age (61.6±6.7 vs. 62.0±7.7years), diabetes duration
      (12.7±6.9 vs. 13.1±5.6years), male proportion (72.7 vs. 86.7%), blood pressure, type of
      diabetes treatment and previous macronutrients intake as well as serum A1C test (6.5±0.6 vs.
      6.7±0.4%), LDL (3.0±1.0 vs. 3.2±0.6mmo/L), HDL (1.3±0.2 vs. 1.3±0.4mmol/L), triacylglycerols
      [1.6(1.0-3.4) vs. 1.6(0.6-3.7)mmol/L], saturated, monounsaturated, and polyunsaturated FAs,
      and trans-unsaturated FAs. The increase in serum glucose and triacylglycerols after the meal
      (ANOVA,P&lt;0.001) was not different in both groups. The maximum increase of FAs occurred at 6-h
      postprandial, but only in TT patients: saturated FAs increased from 464.4(56.9-1602.5) to
      1249.5(214.5-7149.8)mg/dL (P=0.041), monounsaturated FAs from 387.9(30.2-1523.8) to
      925.1(344.6-5554.0)mgd/L (P=0.026), polyunsaturated FAs from 258.9(0-1048.5) to
      713.1(143.7-7987.6)mg/dL (P=0.021), trans-unsaturated FAs from 18.5(1.9-70.6) to
      66.5(5.0-451.7)mg/dL (P=0.023). Conclusion: The presence of the T allele of Ala54Thr
      polymorphism of FABP2 gene in type 2 diabetic patients increases absorption of dietary FAs,
      including the trans-unsaturated FAs, and this might turns these patients more susceptible to
      the effect of diet composition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postprandial serum fatty acids</measure>
    <time_frame>0, 2, 4,6, and 8 hours after meal</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum endothelin serum fibrinogen</measure>
    <time_frame>0 and 8 hours after meal</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Dyslipidemia</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>TT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients homozygous for Thr54 (TT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients homozygous for Ala54 (AA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sandwich</intervention_name>
    <description>standard meal:sandwich (7.23 kcal/kg-total energy; 43.35% fat, 21.95% protein, and 34.70% carbohydrate)</description>
    <arm_group_label>TT</arm_group_label>
    <arm_group_label>AA</arm_group_label>
    <other_name>fat meal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  homozygote to FABP2 polymorphism:TT or AA

        Exclusion Criteria:

          -  age &gt;75 years

          -  glomerular filtration rate &lt;30ml min-1

          -  with unstable angina or possible infarct or stroke in the last year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Weeks</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mirela J Azevedo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2008</study_first_submitted>
  <study_first_submitted_qc>March 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2008</study_first_posted>
  <last_update_submitted>March 12, 2008</last_update_submitted>
  <last_update_submitted_qc>March 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>MIrela Jobim de Azevedo</name_title>
    <organization>Hospital de Clínicas de Porto Alegre</organization>
  </responsible_party>
  <keyword>Serum Fatty Acids</keyword>
  <keyword>FABP2 Gene</keyword>
  <keyword>Polymorphism Ala54Thr</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

